Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ.

J Clin Invest. 2018 Aug 31;128(9):3926-3940. doi: 10.1172/JCI96519. Epub 2018 Aug 13.

2.

LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma.

Kiesel BF, Shogan JC, Rachid M, Parise RA, Vendetti FP, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:158-165. doi: 10.1016/j.jpba.2017.01.055. Epub 2017 Feb 4.

3.

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.

Vendetti FP, Leibowitz BJ, Barnes J, Schamus S, Kiesel BF, Abberbock S, Conrads T, Clump DA, Cadogan E, O'Connor MJ, Yu J, Beumer JH, Bakkenist CJ.

Sci Rep. 2017 Feb 1;7:41892. doi: 10.1038/srep41892.

4.

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.

Vendetti FP, Lau A, Schamus S, Conrads TP, O'Connor MJ, Bakkenist CJ.

Oncotarget. 2015 Dec 29;6(42):44289-305. doi: 10.18632/oncotarget.6247.

5.

Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.

Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM.

Oncotarget. 2015 Jan 1;6(1):56-70.

6.

Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.

Vendetti FP, Rudin CM.

Expert Opin Biol Ther. 2013 Sep;13(9):1273-85. doi: 10.1517/14712598.2013.819337. Epub 2013 Jul 17. Review.

PMID:
23859704
7.

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM.

Cancer Discov. 2011 Dec;1(7):598-607. doi: 10.1158/2159-8290.CD-11-0214. Epub 2011 Nov 9.

Supplemental Content

Loading ...
Support Center